{"prompt": "['Official Title: A Randomized, Multicenter, Open-Label Cross-Over Study to', 'Evaluate Patient Preference and Satisfaction of Subcutaneous', 'Administration of the Fixed-Dose Combination of Pertuzumab and', 'Trastuzumab in Patients With HER2-Positive Early Breast Cancer', 'NCT Number: NCT03674112', 'Document Date: Protocol Version 2: 14-December-2018']['PROTOCOL', 'TITLE:', 'A RANDOMIZED, MULTICENTER, OPEN-LABEL', 'CROSS-OVER STUDY TO EVALUATE PATIENT', 'PREFERENCE AND SATISFACTION OF', 'SUBCUTANEOUS ADMINISTRATION OF THE', 'FIXED-DOSE COMBINATION OF PERTUZUMAB', 'AND TRASTUZUMAB IN PATIENTS WITH HER2-', 'POSITIVE EARLY BREAST CANCER', 'PROTOCOL NUMBER: MO40628', 'VERSION NUMBER:', '2', 'EUDRACT NUMBER:', '2018-002153-30', 'IND NUMBER:', '131009', 'TEST PRODUCT:', 'Fixed-dose combination of pertuzumab and trastuzumab', 'for subcutaneous administration (RO7198574)', 'MEDICAL MONITOR:', 'Dr.', 'SPONSOR:', 'F. Hoffmann-La Roche Ltd', 'DATE FINAL:', 'Version 1: 24 July 2018', 'DATE AMENDED:', 'Version 2: See electronic date stamp below', 'PROTOCOL AMENDMENT APPROVAL', \"Approver's Name\", 'Title', 'Date and Time (UTC)', 'Company Signatory', '14-Dec-2018 13:59:04', 'CONFIDENTIAL', 'This clinical study is being sponsored globally by F. Hoffmann-La Roche Ltd of Basel,', \"Switzerland. However, it may be implemented in individual countries by Roche's local affiliates, including\", 'Genentech, Inc. in the United States. The information contained in this document, especially any', 'unpublished data, is the property of F. Hoffmann-La Roche Ltd (or under its control) and therefore is', 'provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your', 'staff, and an applicable Ethics Committee or Institutional Review Board. It is understood that this', 'information will not be disclosed to others without written authorization from Roche except to the extent', 'necessary to obtain informed consent from persons to whom the drug may be administered.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', 'Protocol MO40628, Version 2']['PROTOCOL AMENDMENT, VERSION 2:', 'RATIONALE', 'Protocol MO40628 has been amended to correct minor errors and to provide clarification on', 'several protocol details. Changes to the protocol, along with a rationale for each change,', 'are summarized below:', 'Sections Affected', 'Rationale for Change', '4.1.1', 'Hormone receptor status was incorrectly referred to as', '\"hormone receptor-positive status\" in the inclusion criteria.', 'This error has been corrected.', '4.5.11; Appendix 1', 'Albumin has been added as part of blood chemistry at', '(Schedule of', 'Screening, for determination of patient eligibility.', 'Assessments)', '5.2.4.3', 'Reporting conventions have been added for local infusion', 'reactions.', '6,6.6, 9.4', 'An interim analysis will now be conducted to support a', 'planned regulatory filing for FDC. The scope of this interim will', 'be a subset of the analyses planned for the primary analysis.', 'Appendix 1 (Schedule of', 'The timing of pregnancy tests during the Treatment Cross-', 'Assessments)', 'over and Treatment Continuation Periods has been clarified.', 'It has been clarified that pregnancy testing is only required for', 'women of childbearing potential.', 'Appendix 1 (Schedule of', 'The Schedule of Assessments has been revised to clarify that', 'Assessments)', 'adverse events and concomitant medications are collected on', 'an ongoing basis throughout the Treatment Cross-Over', 'Period and the Treatment Continuation Period.', 'Appendix 1 (Schedule of', 'It has been clarified that, for all protocol-mandated study', 'Assessments)', 'visits, a time window of 3 days is allowed.', 'Appendix 1 (Schedule of', 'It has been clarified that no specific investigations are', 'Assessments)', 'required per protocol for Cycles 8-10 and Cycles 12-14 during', 'the Treatment Continuation Period, although the investigator', 'may perform safety laboratory assessments or other tests per', 'institutional practice. Information on treatment administration', 'as well as any new or worsened clinically significant', 'abnormalities will be collected.', 'Appendix 7', 'An error in the definition of Grade 4 left ventricular systolic', 'dysfunction (LVSD) has been corrected.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '2 / Protocol MO40628, Version 2']\n\n###\n\n", "completion": "END"}